Publication
If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study
| dc.contributor.author | Beldman, Mark | |
| dc.contributor.author | Löwik, Claudia | |
| dc.contributor.author | Soriano, Alex | |
| dc.contributor.author | Albiach, Laila | |
| dc.contributor.author | Zijlstra, Wierd P | |
| dc.contributor.author | Knobben, Bas A S | |
| dc.contributor.author | Jutte, Paul | |
| dc.contributor.author | Sousa, Ricardo | |
| dc.contributor.author | Carvalho, André | |
| dc.contributor.author | Goswami, Karan | |
| dc.contributor.author | Parvizi, Javad | |
| dc.contributor.author | Belden, Katherine A | |
| dc.contributor.author | Wouthuyzen-Bakker, Marjan | |
| dc.date.accessioned | 2023-10-24T11:12:15Z | |
| dc.date.available | 2023-10-24T11:12:15Z | |
| dc.date.issued | 2021-11 | |
| dc.description.abstract | Background: Rifampin is generally advised in the treatment of acute staphylococcal periprosthetic joint infections (PJI). However, if, when, and how to use rifampin remains a matter of debate. We evaluated the outcome of patients treated with and without rifampin, and analyzed the influence of timing, dose and co-antibiotic. Methods: Acute staphylococcal PJIs treated with surgical debridement between 1999 and 2017, and a minimal follow-up of 1 year were evaluated. Treatment failure was defined as the need for any further surgical procedure related to infection, PJI-related death or the need for suppressive antimicrobial treatment. Results: A total of 669 patients were analyzed. Treatment failure was 32.2% (131/407) in patients treated with rifampin and 54.2% (142/262) in whom rifampin was withheld (P < .001). The most prominent effect of rifampin was observed in knees (treatment failure 28.6% versus 63.9%, respectively, P < .001). The use of rifampin was an independent predictor of treatment success in the multi-variate analysis (OR 0.30, 95% CI 0.20 - 0.45). In the rifampin group, the use of a co-antibiotic other than a fluoroquinolone or clindamycin (OR 10.1, 95% CI 5.65 - 18.2) and the start of rifampin within 5 days after surgical debridement (OR 1.96, 95% CI 1.08 - 3.65) were predictors of treatment failure. The dosing of rifampin had no effect on outcome. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Beldman M, Löwik C, Soriano A, et al. If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study [published correction appears in Clin Infect Dis. 2022 May 30;74(10):1890]. Clin Infect Dis. 2021;73(9):1634-1641. doi:10.1093/cid/ciab426 | pt_PT |
| dc.identifier.doi | 10.1093/cid/ciab426 | pt_PT |
| dc.identifier.issn | 1058-4838 | |
| dc.identifier.issn | 1537-6591 | |
| dc.identifier.uri | http://hdl.handle.net/10400.16/2846 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Oxford University Press | pt_PT |
| dc.relation.publisherversion | https://academic.oup.com/cid/article/73/9/1634/6273129?login=false | pt_PT |
| dc.subject | acute | pt_PT |
| dc.subject | failure | pt_PT |
| dc.subject | periprosthetic joint infection | pt_PT |
| dc.subject | rifampin | pt_PT |
| dc.subject | staphylococci | pt_PT |
| dc.title | If, When, and How to Use Rifampin in Acute Staphylococcal Periprosthetic Joint Infections, a Multicentre Observational Study | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | United States of America | pt_PT |
| oaire.citation.endPage | 1641 | pt_PT |
| oaire.citation.issue | 9 | pt_PT |
| oaire.citation.startPage | 1634 | pt_PT |
| oaire.citation.title | Clinical Infectious Diseases | pt_PT |
| oaire.citation.volume | 73 | pt_PT |
| person.familyName | Sousa | |
| person.givenName | Ricardo | |
| person.identifier.ciencia-id | 8C18-816F-6E4A | |
| person.identifier.orcid | 0000-0003-4293-7347 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isAuthorOfPublication | 2f21d3c0-c752-499f-9bcc-d87d9fd31d5c | |
| relation.isAuthorOfPublication.latestForDiscovery | 2f21d3c0-c752-499f-9bcc-d87d9fd31d5c |